Mediso

Executive Summary

Mediso is a Hungarian medical device company with over 50 years of history, specializing in advanced molecular imaging systems. Founded in 1972, the company has evolved from a general medical device manufacturer to a focused provider of nuclear medicine (NM) and hybrid imaging solutions, including SPECT, PET, CT, and MRI. Its product portfolio centers on the AnyScan® platform for clinical use and the nanoScan® platform for preclinical research, serving hospitals, clinics, and scientific institutions worldwide. Mediso is privately held and has established a global presence, though financial details and recent funding rounds are not publicly disclosed. The company operates in the competitive medical imaging market, where differentiation depends on image quality, throughput, and integration with complementary modalities. Given its long track record and focus on hybrid systems, Mediso is well-positioned to benefit from the growing demand for precision diagnostics in oncology, cardiology, and neurology. However, as a private company with limited public information, the investment opportunity carries moderate uncertainty. The company's stage is listed as pre-clinical, but this may refer to its pipeline rather than its commercial status, as Mediso has commercial products on the market. Overall, Mediso represents a niche player in molecular imaging with potential for steady growth through incremental innovation and expansion into emerging markets.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation AnyScan® system with AI-enhanced reconstruction70% success
• Q1 2027FDA clearance for a new SPECT/CT indication in cardiology60% success
• Q4 2026Strategic partnership or distribution agreement in Asia-Pacific region50% success